Every 10-Q that Hinge Health, Inc. (HNGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HNGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HNGE filings page.
Hinge Health, Inc., a digital MSK and migraine care company, reported strong results for the three and six months ended June 30, 2026. Revenue was 212,817 and 395,124 (in thousands), with gross profit of 183,949 and 338,182 (in thousands). Income from operations reached 40,440 and 72,509 (in thousands), and net income was 43,690 and 78,818 (in thousands), compared with net losses of 575,651 and 558,512 (in thousands) in 2025.
Net cash provided by operating activities rose to 144,496 (in thousands) for the first half of 2026. As of June 30, 2026, cash and cash equivalents were 286,224 (in thousands) and marketable securities totaled 187,909 (in thousands). Deferred revenue increased to 416,466 (in thousands), and stockholders’ equity improved to 344,328 (in thousands) as redeemable convertible preferred stock was fully converted. The company repurchased and retired 2,934,671 Class A shares for 131,491 (in thousands) and expanded its share repurchase authorization to an aggregate 496.5 million of Class A common stock.
Management highlights risks including a history of accumulated deficits, heavy reliance on AI-driven care, evolving healthcare and telehealth regulation, supplier concentration for its Enso device, and dependence on health-plan partners. A dual class structure concentrates voting control with the founders, and the company expects to become a large accelerated filer and cease emerging growth company status as of December 31, 2026.
Hinge Health, Inc. reported strong first-quarter 2026 results, with revenue of $182.3 million, up from $123.8 million a year earlier, driven by its AI-powered musculoskeletal care platform.
Net income rose to $35.1 million from $17.1 million, and diluted earnings per share were $0.41. Operating cash flow improved to $43.1 million from $4.9 million, supporting a significant capital return: the company repurchased and cancelled 2.45 million Class A shares for $105.8 million under its $250 million buyback program, leaving $80.0 million authorized for future repurchases.
The balance sheet showed total assets of $728.8 million, including $186.7 million of cash and cash equivalents and $219.0 million of marketable securities, alongside deferred revenue of $340.8 million that reflects future subscription obligations. Hinge Health continues to invest heavily in growth, with research and development, sales and marketing, and general and administrative expenses totaling $122.2 million, and recorded $11.7 million of stock-based compensation as it scales its workforce and technology.
Hinge Health (HNGE) reported Q3 2025 results showing strong top-line growth with ongoing investment-driven losses. Revenue reached $154.2 million, up from $100.6 million a year ago, as more clients and members used its musculoskeletal care platform. Gross profit was $126.2 million.
Operating loss was $6.1 million and net loss was $1.8 million for the quarter. For the first nine months of 2025, revenue totaled $417.1 million versus $273.1 million a year ago, while a large increase in operating expenses, including stock-based compensation, drove a net loss of $560.4 million. The company ended the quarter with $261.3 million in cash and cash equivalents and $233.8 million in marketable securities, and generated $107.5 million of operating cash flow year-to-date. Deferred revenue rose to $299.7 million, reflecting billed but not yet recognized subscription revenue.
Hinge Health reported strong top-line growth alongside a large non-cash expense related to equity awards after completing its IPO. Revenue for the three months ended June 30, 2025 was $139.1 million, up from $89.8 million a year earlier, producing a gross profit of $97.8 million. Billings and deferred revenue increased, with deferred revenue at $275.1 million at June 30, 2025, reflecting billed but unrecognized subscription obligations.
Despite revenue growth, operating expenses surged to $678.4 million for the quarter, driven primarily by stock-based compensation. The company recorded a quarterly net loss of $575.7 million and an accumulated deficit of $1.08 billion. Cash and marketable securities remain substantial with cash and cash equivalents of $237.2 million and marketable securities of $176.1 million. In May 2025 the company completed an IPO, reclassified and converted preferred shares into common stock, repurchased Series E shares from a holder for $50.0 million, and used IPO proceeds to pay employee tax liabilities on equity settlements.